EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ ( PATROL) study

Heather H Cheng, Kara N Maxwell, Keyan Salari, Matthew R Cooperberg, Kristin Follmer, Joanne M Jeter, Grace Jun, Daniel J Lee, Hiten D Patel, Edward M Schaeffer iD, Alexandra O Sokolova, Erika M Wolff und 1 weitere

BJU International · 2026

DOI: 10.1111/bju.70334 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, 2026. Verfasst von Heather H Cheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Early Detection of Cancer, Genetic Predisposition to Disease, Prostatic Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: DOD Prostate Cancer Research Program, NCI NIH HHS, The Basser Center for BRCA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines—e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53 . However, the optimal early detection strategy for gPV carriers, including use of age‐adjusted PSA thresholds and prostate imaging may be refined. and as a means to investigate novel biomarkers. Study Design ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) is a multicentre, prospective early detection study for individuals at increased risk for PCa due to carrying a gPV in a PCa risk gene. Endpoints The primary endpoint is to determine the positive predictive value of pre‐defined age‐directed prostate‐specific antigen (PSA) level thresholds and prostate‐specific imaging, e.g., multiparametric magnetic resonance imaging (MRI) for clinically significant PCa on biopsy for individuals at risk of PCa due to a gPV. Exploratory endpoints include characterising clinicopathological characteristics of PCa and patient‐reported outcomes. Biospecimens will be collected to evaluate emerging clinical and research biomarkers. Patients and Methods Key eligibility includes: individuals aged ≥40 years who carry a gPV in an eligible gene, who have no prior diagnosis of PCa, do not have another active malignancy, and provide informed consent. Study procedures include annual physical examination and PSA. Imaging with MRI is optional at baseline and recommended if the PSA level is above the protocol‐recommended PSA level threshold. Participants will be offered prostate biopsy for any clinical concern, PSA level >1.0 ng/mL if aged 1.5 ng/mL if aged 50–59 years; PSA level >2.0 ng/mL if aged ≥60 years. If PCa is diagnosed, clinical care is determined by the participant and treating physician. If opting for active surveillance, study procedures will be collected annually for 10 years or until definitive treatment. If definitive treatment, study procedures will be collected for an additional 1 year. Long‐term clinical outcomes will be collected annually until the study closes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerGenetic Predisposition to DiseaseProstatic NeoplasmsHumansMaleMiddle AgedGenetic TestingMagnetic Resonance ImagingProspective StudiesProstate-Specific Antigen

Stichwörter der Autor:innen

BRCA1/2early detectiongenetic riskprostate cancerprostate‐specific antigenriskscreening

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Medicine, University of Washington, Seattle, WA, USA.
  • Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Department of Medicine-Hematology/Oncology, Department of Genetics and Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Urology, University of California, San Francisco, San Francisco, CA, USA.
  • Department of Urology, University of Washington, Seattle, WA, USA.

ORCID-Profile: Edward M Schaeffer

Förderung

  • DOD Prostate Cancer Research Program
  • NCI NIH HHS
  • The Basser Center for BRCA
  • The Institute for Prostate Cancer Research
  • NIH HHS
  • Polsky Urologic Cancer Institute
  • The Canary Foundation
  • BRCA Research and Cure Alliance (CureBRCA)

Zitieren

APA

Cheng, H. H., Maxwell, K. N., Salari, K., Cooperberg, M. R., Follmer, K., Jeter, J. M., Jun, G., Lee, D. J., Patel, H. D., Schaeffer, E. M., Sokolova, A. O., Wolff, E. M., & Lin, D. W. (2026). The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ ( PATROL) study. BJU International. https://doi.org/10.1111/bju.70334

Vancouver

Cheng HH, Maxwell KN, Salari K, Cooperberg MR, Follmer K, Jeter JM, et al. The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ ( PATROL) study. BJU International. 2026. doi:10.1111/bju.70334

BibTeX
@article{Cheng2026,
  author = {Cheng, Heather H and Maxwell, Kara N and Salari, Keyan and Cooperberg, Matthew R and Follmer, Kristin and Jeter, Joanne M and Jun, Grace and Lee, Daniel J and Patel, Hiten D and Schaeffer, Edward M and Sokolova, Alexandra O and Wolff, Erika M and Lin, Daniel W},
  title = {The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ ( PATROL) study},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.70334}
}
Kostenlos starten →